Inventor · disambiguated record
Mark Throsby
Also filed as: THROSBY MARK
46 granted patents·25 pending applications·606 citations·filing 2006–2025
98Inventor score
Top patents by PatentIndex Score
71 records- 0197US8691223B2Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereofVAN DEN BRINK EDWARD NORBERT·Filed 2011·Granted Apr 8, 2014·63 cites·12 claims
- 0296US12139548B2Antibody that binds ErbB-2 and ErbB-3MERUS NV·Filed 2022·Granted Nov 12, 2024·4 cites·20 claims
- 0396US8192927B2Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereofVAN DEN BRINK EDWARD NORBERT·Filed 2007·Granted Jun 5, 2012·53 cites·11 claims
- 0496US7960518B2Human binding molecules having killing activity against enterococci and uses thereofCRUCELL HOLLAND BV·Filed 2007·Granted Jun 14, 2011·45 cites·11 claims
- 0595US12247078B2ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion geneMERUS NV·Filed 2024·Granted Mar 11, 2025·3 cites·20 claims
- 0695US10605808B2Antibody producing non-human animalsMERUS NV·Filed 2016·Granted Mar 31, 2020·19 cites·9 claims
- 0795US9765133B2Antibody producing non-human mammalsMERUS B V·Filed 2014·Granted Sep 19, 2017·12 cites·5 claims
- 0895US9145588B2Generation of binding moleculesMERUS B V·Filed 2012·Granted Sep 29, 2015·69 cites·10 claims
- 0995US8241631B2Human binding molecules having killing activity against enterococci and uses thereofTHROSBY MARK·Filed 2011·Granted Aug 14, 2012·31 cites·10 claims
- 1095US8052974B2Host cell specific binding molecules capable of neutralizing viruses and uses thereofCRUCELL HOLLAND BV·Filed 2006·Granted Nov 8, 2011·34 cites·5 claims
- 1195US7244430B2Binding molecules capable of neutralizing West Nile virus and uses thereofCRUCELL HOLLAND BV·Filed 2007·Granted Jul 17, 2007·28 cites·7 claims
- 1294US11237165B2Antibody producing non-human animalsMERUS NV·Filed 2017·Granted Feb 1, 2022·5 cites·14 claims
- 1394US9944695B2Antibody producing non-human mammalsMERUS B V·Filed 2014·Granted Apr 17, 2018·8 cites·3 claims
- 1494US8470327B2Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereofTHROSBY MARK·Filed 2010·Granted Jun 25, 2013·41 cites·39 claims
- 1593US8211431B2Human binding molecules having killing activity against staphylococci and uses thereofTHROSBY MARK·Filed 2007·Granted Jul 3, 2012·37 cites·12 claims
- 1692US10844127B2Antibodies that bind EGFR and ErbB3MERUS NV·Filed 2015·Granted Nov 24, 2020·8 cites·18 claims
- 1792US10647781B2Generation of binding moleculesMERUS NV·Filed 2017·Granted May 12, 2020·6 cites·7 claims
- 1892US8911738B2Host cell specific binding molecules capable of neutralizing viruses and uses thereofTHROSBY MARK·Filed 2011·Granted Dec 16, 2014·18 cites·5 claims
- 1991US11820825B2Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumorMERUS NV·Filed 2020·Granted Nov 21, 2023·2 cites·12 claims
- 2091US11408095B2Generation of binding moleculesMERUS NV·Filed 2020·Granted Aug 9, 2022·2 cites·7 claims
- 2191US9908946B2Generation of binding moleculesMERUS B V·Filed 2015·Granted Mar 6, 2018·6 cites·7 claims
- 2291US9428572B2Human binding molecules having killing activity against enterococciCRUCELL HOLLAND BV·Filed 2013·Granted Aug 30, 2016·11 cites·13 claims
- 2391US7537764B2Binding molecules capable of neutralizing west nile virus and uses thereofCRUCELL HOLLAND BV·Filed 2006·Granted May 26, 2009·11 cites·15 claims
- 2490US11279770B2Antibody that binds ErbB-2 and ErbB-3MERUS NV·Filed 2015·Granted Mar 22, 2022·7 cites·17 claims
- 2589US11559049B2Antibody producing non-human animalsMERUS NV·Filed 2018·Granted Jan 24, 2023·2 cites·7 claims
- 2687US11732043B2Antibodies that modulate a biological activity expressed by a cellMERUS NV·Filed 2018·Granted Aug 22, 2023·3 cites·22 claims
- 2787US8642513B2Method for preparing immunoglobulin librariesTHROSBY MARK·Filed 2006·Granted Feb 4, 2014·8 cites·22 claims
- 2887US7968092B2Human binding molecule against CD1aCRUCELL HOLLAND BV·Filed 2006·Granted Jun 28, 2011·31 cites·5 claims
- 2987US2024023527A1Antibody producing non-human animalsMERUS NV·Filed 2023·Application pending·0 cites
- 3087US2024156072A1Antibody producing non-human animalsMERUS NV·Filed 2023·Application pending·0 cites
- 3186US11780925B2ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion geneMERUS NV·Filed 2018·Granted Oct 10, 2023·5 cites·15 claims
- 3286US10966411B2Antibody producing non-human mammalsLOGTENBERG TON·Filed 2009·Granted Apr 6, 2021·3 cites·14 claims
- 3386US8628776B2Human binding molecules against enterococci and StaphylococcusTHROSBY MARK·Filed 2012·Granted Jan 14, 2014·6 cites·10 claims
- 3486US8460666B2Human binding molecules having killing activity against staphylococci and uses thereofTHROSBY MARK·Filed 2012·Granted Jun 11, 2013·7 cites·15 claims
- 3585US11667714B2Binding molecules that modulate a biological activity expressed by a cellMERUS NV·Filed 2018·Granted Jun 6, 2023·3 cites·48 claims
- 3684US12091461B2Bispecific antibodyONO PHARMACEUTICAL CO·Filed 2021·Granted Sep 17, 2024·1 cites·36 claims
- 3783US2024158532A1Antibody that binds erbb-2 and erbb-3MERUS NV·Filed 2024·Application pending·0 cites
- 3882US12325746B2Bispecific antibodyONO PHARMACEUTICAL CO·Filed 2020·Granted Jun 10, 2025·1 cites·6 claims
- 3982US11753470B2Bispecific anti PD1-anti TIM3 antibodiesMERUS NV·Filed 2018·Granted Sep 12, 2023·2 cites·14 claims
- 4081US12291798B2Generation of binding moleculesMERUS NV·Filed 2022·Granted May 6, 2025·0 cites·12 claims
- 4181US11091550B2Bispecific antibodyONO PHARMACEUTICAL CO·Filed 2019·Granted Aug 17, 2021·2 cites·9 claims
- 4281US2024158531A1Antibody that binds erbb-2 and erbb-3MERUS NV·Filed 2024·Application pending·0 cites
- 4381US2025230579A1Generation of binding moleculesMERUS NV·Filed 2025·Application pending·0 cites
- 4480US11939394B2Binding molecules that inhibit cancer growthMERUS NV·Filed 2016·Granted Mar 26, 2024·4 cites·30 claims
- 4579US9611317B2Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereofCRUCELL HOLLAND BV·Filed 2013·Granted Apr 4, 2017·2 cites·11 claims
- 4678US2022348683A1Antibody that binds erbb-2 and erbb-3MERUS NV·Filed 2022·Application pending·0 cites
- 4778US2024052043A1Antibodies that bind egfr and erbb3MERUS NV·Filed 2023·Application pending·0 cites
- 4878US2024199747A1Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion geneMERUS NV·Filed 2023·Application pending·0 cites
- 4976US11685786B2Binding molecules that bind CD137 and PD-L1MERUS NV·Filed 2017·Granted Jun 27, 2023·1 cites·10 claims
- 5076US2024287187A1Bispecific antibodyONO PHARMACEUTICAL CO·Filed 2024·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark Throsby files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →